(Refiled for typo in first paragraph)
Nov 9 (Reuters) - Sage Therapeutics on Thursday said its drug to treat moderate and severe postpartum depression met the main goal in two late-stage studies.
The drug, brexanolone, achieved lower rates of depression in patients compared with a placebo in both trials.
Postpartum depression is a common complication of childbirth that affects about 10 to 20 percent of women giving birth in the United States, the company said. (Reporting by Tamara Mathias in Bengaluru; Editing by Bernard Orr)